Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
Montero
Alberto
A
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1439, USA.
Booser
Daniel
D
Esparza-Guerra
Laura
L
Murray
James
J
Rosales
Marguerite
M
Hortobagyi
Gabriel
G
Valero
Vicente
V
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D043823:Taxoids; D000077143:Docetaxel; C081222:sargramostim; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor